Close Menu

NEW YORK (GenomeWeb News) – Sequencing technology firm PathoGenetix has raised $3.6 million, it said in a regulatory filing.

In the document filed with the US Securities and Exchange Commission on Tuesday, the Woburn, Mass.-based firm said it is targeting $9.1 million in the current offering. The type of securities being offered is in the form of equity. The company did not identify the investors or say how it plans to use the funding.

A company official did not respond to an e-mail requesting comment.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.

In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.

MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.

In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.

Aug
29
Sponsored by
PerkinElmer

This webinar will outline how RUCDR Infinite Biologics, the world's largest university-based biorepository, has implemented workflows and processes to support precision medicine applications.

Sep
16
Sponsored by
ArcherDX

This webinar will discuss a next-generation sequencing approach for detecting genomic mutations in hematologic maglignancies.

Sep
18
Sponsored by
Bionano Genomics

This webinar will outline how a team at Radboud University Medical Center is assessing ultra-long read optical mapping on the Bionano Saphyr system to replace classical cytogenetics approaches in routine testing and for the discovery of novel structural variants with potential scientific, prognostic, or therapeutic value that are missed by standard approaches.

Oct
03
Sponsored by
Agilent

This webinar will provide an overview of how an international reference laboratory has implemented an automated next-generation sequencing workflow with custom panels for analyzing cancer samples.